0001575142falsefalse00015751422025-03-132025-03-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 13,2025
BIOADAPTIVES, INC. |
(Exact Name of Registrant as Specified in its Charter) |
Delaware | | 000-54949 | | 46-2592228 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
2620 Regatta Drive, Suite 102
Las Vegas, Nevada 89128
(Address of Principal Executive Office) (Zip Code)
(702) 659-8829
Registrant's telephone number, including area code:
N/A
(former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
The Company issued a press release on March 13, 2025, announcing its Zeranovia(TM) Weight Loss Product Showing Promising Results in Dosage Trial
A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| March 17, 2025 | | BioAdaptives, Inc. | |
| | | | |
| | /s/ James E, Keener | |
| | James E, Keener, CEO | |
EXHIBIT 99.1
Zeranovia™ Weight Loss Product Shows Promising Results in Dosage Trial
LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone.
During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was easily managed by increasing water intake or adjusting the product dosage.
“We are thrilled with the results of this dosage trial,” said James Keener, CEO. “The consistent weight loss across participants, coupled with the manageable side effect profile, indicates that Zeranovia™ has the potential to be a game-changer in the weight loss market.”
Key findings from the dosage trial include:
Consistent weight loss across participants
Minimal side effects, easily managed with simple adjustments
High participant satisfaction, with all trial subjects requesting to proceed to the next phase
Based on these promising results, BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials. The company is optimistic about the product's potential to address the growing global need for effective and safe weight loss solutions.
“The enthusiasm from our trial participants is incredibly encouraging,” added Keener. “Their eagerness to continue with the next phase of testing speaks volumes about the product's effectiveness and tolerability.”
BioAdaptives is committed to developing innovative solutions for weight management. The company anticipates releasing further updates as the clinical trial progresses.
About BioAdaptives, Inc.
BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.
For more information, please visit our website at www.bioadaptives.com.
Contact Information:
BioAdaptives, Inc.
Emily Harrison
IR Coordinator
(702)-659-8829
2620 Regatta Dr, Suite 102
Las Vegas, NV 89128
Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.